Vadimezan

From Self-sufficiency
Jump to: navigation, search
Vadimezan
File:Vadimezan.png
Systematic (IUPAC) name
(5,6-Dimethyl-9-oxo-9H-xanthen-4-yl)-acetic acid
Identifiers
CAS Number 117570-53-3
ATC code none
Synonyms ASA404, DMXAA
Chemical data
Formula C17H14O4
Molar mass 282.29 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Vadimezan or ASA404 (originally DMXAA)[1] is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.[2]

Clinical trials

Vadimezan has been studied in combination with chemotherapy in at least two Phase II trials for advanced non-small cell lung cancer (NSCLC) and has shown survival extensions of around 5 months when compared to chemotherapy alone (14.0 months compared to 8.8 months).[3][4] In April 2008, a Phase III trial started. In March 2010 the phase III trial of use as a first line therapy for NSCLC gave poor results[5]. Initerim results on another phase III trial as second-line therapy for NSCLC are due later in 2010 with the trial due to complete in 2011.

It is being studied for the treatment of prostate cancer[4] and HER2-negative metastatic breast cancer.[1][6]

History

ASA404 was discovered by Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre at the University of Auckland in New Zealand.[6] It was licensed to Antisoma in 2001. Novartis acquired the worldwide rights for it in 2007 and it is being developed by Antisoma and Novartis.[4][6]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


Stub icon This pharmacology-related article is a stub. You can help ssf by expanding it.
  1. ↑ 1.0 1.1 "New Zealand drug tested for breast-cancer fight". New Zealand Herald. 14 February 2009. Retrieved 2009-02-13. 
  2. ↑ ASA404, A Novel Cancer Agent, Begins Pivotal Trial To Explore New Approach In Treating Lung Cancer, The Leading Cause Of Cancer Death, Medical News Today, 14 Apr 2008
  3. ↑ MJ McKeage; et al. (2008). "Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer". Br J Cancer. 99 (12): 2006. doi:10.1038/sj.bjc.6604808. PMC 2607218 Freely accessible. PMID 19078952. 
  4. ↑ 4.0 4.1 4.2 ASA404 Vascular Disrupting Agent for Solid Tumours, drugdevelopment-technology.com
  5. ↑ http://www.genengnews.com/news/bnitem.aspx?name=78979622 "Antisoma’s Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial"
  6. ↑ 6.0 6.1 6.2 "ASA404 to be developed in breast cancer". Antisoma. 12 February 2009. Retrieved 2009-02-13. 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Vadimezan&oldid=23705"